为农药flupyradifurone开发与CHARMM兼容的力场参数和分子动力学模拟
Zakaria Bouchouireb1, Steeve H Thany2, Jean-Yves Le Questel1
1Nantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Journal of computational chemistry
|November 15, 2023
概括
为flupyradifurone (FLU) 开发了优化的CHARMM力场参数. 这些参数可以准确地预测FLU.
科学领域:
- 计算化学是一种计算化学.
- 分子动力学分子动力学
- 杀虫剂研究 杀虫剂研究
背景情况:
- 皮拉迪 (FLU) 是一种类杀虫剂,向昆虫的尼古丁酸乙胆受体.
- 有关FLU对非标生物的安全性存在担忧,需要进一步的毒理学和机理学研究.
研究的目的:
- 为flupyradifurone (FLU) 开发和验证优化的CHARMM兼容的力场参数.
- 为了实现FLU相互作用和行为的精确分子模拟.
主要方法:
- 作为基础,使用了CHARMM通用部队现场计划.
- 优化了非结合和结合参数,以实现MP2/6-31G的准确性.
- 验证涉及对实验数据计算红外光谱,分区系数和正常模式.
- 分子动力学模拟在水溶液中进行,并使用一种乙胆结合蛋白.
主要成果:
- 成功生成了针对FLU的优化CHARMM参数.
- 计算的特性 (红外频谱,分区系数,正常模式) 与实验值有很好的一致性.
- 分子动力学模拟表明参数能够描述FLU的扭转空间和晶体学趋势.
结论:
- 开发的CHARMM参数为模拟flupyradifurone提供了一个可靠的工具.
- 这项工作有助于进一步研究FLU的分子机制和潜在的毒理作用.
更多相关视频
07:31Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches
Published on: September 1, 2023
2.3K
05:00Author Spotlight: Streamlining Visual Dynamics to Simplify Molecular Dynamics Simulations Using Gromacs
Published on: August 9, 2024
1.3K
相关概念视频
Molecular Models
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
